The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Operational Update

19 Jun 2020 14:29

RNS Number : 5454Q
Braveheart Investment Group plc
19 June 2020
 

19 June 2020

Braveheart Investment Group plc

("Braveheart" or "the Group")

 

Further re. Operational Update

 

Braveheart Investment Group (AIM: BRH), reports that, further to the announcement on 23 April 2020 regarding the increase in production capacity to 2,000 litres per day by the end of May by Pharm 2 Farm Limited ("P2F") (holding 51.72%) of medical grade alcohol hand sanitiser gel, this was achieved on schedule and as planned. However, the market price of medical grade hand sanitiser has fallen steadily from an average of approximately £25 per litre in April 2020 to a current price of approximately £3 per litre. In addition, certain producers are now providing medical grade hand sanitiser free of charge to certain organisations.

In light of the steep decline in the price of medical grade hand sanitiser and the continuing demand for nanoparticle production, P2F has decided to switch its production capabilities back to nanoparticle production and to cease the production of medical grade hand sanitiser. Two new reactors were commissioned by P2F this week, both capable of producing over 10kg per hour of nanoparticles each. This extra capacity will feed into existing and new projects, including hydroponic plant feed, combating citrus greening disease and COVID-19 face mask protection.

 

For further information: 

 

 

 

 

Braveheart Investment Group plc

Tel: 01738 587555

Viv Hallam, Executive Director

 

 

 

Allenby Capital Limited (Nominated Adviser and Joint Broker)

Tel: 020 3328 5656

David Worlidge / Nicholas Chambers

 

 

 

Peterhouse Capital Limited (Joint Broker)

Tel: 020 7469 0936

Heena Karani / Lucy Williams

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURFLMJTMTTBBRM

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.